Last reviewed · How we verify
FF nasal spray
At a glance
| Generic name | FF nasal spray |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) (PHASE4)
- Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR) (PHASE3)
- Fluticasone Nasal Spray Patient Preference Study (PHASE3)
- Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays (PHASE4)
- Intranasal Steroids and Oxymetazoline in Allergic Rhinitis (PHASE4)
- Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF nasal spray CI brief — competitive landscape report
- FF nasal spray updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI